| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/18/2009 | CA2709083A1 Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
| 06/18/2009 | CA2708719A1 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| 06/18/2009 | CA2708606A1 Methods of treating hematologic cancers |
| 06/18/2009 | CA2708264A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| 06/18/2009 | CA2708149A1 Combinations of therapeutic agents for treating cancer |
| 06/18/2009 | CA2708137A1 Use |
| 06/18/2009 | CA2707313A1 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 06/18/2009 | CA2706811A1 Novel 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals |
| 06/18/2009 | CA2706806A1 Novel 2-substituted tiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals |
| 06/18/2009 | CA2705467A1 Compounds and methods for the treatment of cancer |
| 06/18/2009 | CA2700599A1 Pyrazolo-pyrazines derivatives used as g protein inhibitors |
| 06/18/2009 | CA2700559A1 Nicotinamide derivatives, preparation thereof and therapeutic use thereof |
| 06/17/2009 | EP2071036A2 Methods for identifying RNA-binding compounds |
| 06/17/2009 | EP2070971A1 Compound of resorcinol derivative with polymer |
| 06/17/2009 | EP2070949A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 06/17/2009 | EP2070947A1 Therapeutic and diagnostic anti-Hsp70 antibodies |
| 06/17/2009 | EP2070944A1 Specific binding agents of human angiopoietin-2 |
| 06/17/2009 | EP2070939A1 Modulators of pharmacological agents |
| 06/17/2009 | EP2070928A1 7-azaindol-3-ylacrylamides active as kinase inhibitors |
| 06/17/2009 | EP2070925A1 New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
| 06/17/2009 | EP2070924A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
| 06/17/2009 | EP2070921A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 06/17/2009 | EP2070919A1 Spiroquinone compound and pharmaceutical composition |
| 06/17/2009 | EP2070914A1 New antagonist derivatives of the vitronectin receiver, method for preparing same, application of same as medicine and pharmaceutical compositions containing them |
| 06/17/2009 | EP2070909A1 Non-steroidal progesterone receptor modulators |
| 06/17/2009 | EP2070908A1 Compound having benzamide skeleton and cyclooxygenase (cox-1)-selective inhibitory activity |
| 06/17/2009 | EP2070548A1 Diagnosis and treatment of cancer using anti-ereg antibody |
| 06/17/2009 | EP2070547A1 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor |
| 06/17/2009 | EP2070546A1 Preventives/remedies for cancer |
| 06/17/2009 | EP2070542A2 Method of extended culture of antigen-specific cyotoxic T lymphocytes |
| 06/17/2009 | EP2070537A1 Crystalline polymorphs of topotecan hydrochloride and methods for the preparation thereof |
| 06/17/2009 | EP2070534A2 Cyclopropyl and cyclobutyl epothilone analogs |
| 06/17/2009 | EP2069794A1 Grp78 as a predictor of responsiveness to therapeutic agents |
| 06/17/2009 | EP2069501A2 Rna interference against wrap53 to treat hyperproliferative diseases |
| 06/17/2009 | EP2069498A1 Inhibitory polynucleotide compositions and methods for treating cancer |
| 06/17/2009 | EP2069404A1 Humanized anti-cd100 antibodies |
| 06/17/2009 | EP2069371A1 Organo-arsenoxide compounds and use thereof |
| 06/17/2009 | EP2069359A1 Aza-benzothiophenyl compounds and methods of use |
| 06/17/2009 | EP2069354A1 Aza-benzofuranyl compounds and methods of use |
| 06/17/2009 | EP2069350A2 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 06/17/2009 | EP2069349A2 Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 06/17/2009 | EP2069348A2 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 06/17/2009 | EP2069345A2 Pyridazine and pyrrole compounds, processes for obtaining them and uses |
| 06/17/2009 | EP2069342A1 2-aryl-6-phenylimidazo[1,2-alpha]pyridine derivatives, preparation thereof and therapeutic use thereof |
| 06/17/2009 | EP2069336A1 Pyridin-4-yl derivatives as immunomodulating agents |
| 06/17/2009 | EP2069335A1 Pyridin-3-yl derivatives as immunomodulating agents |
| 06/17/2009 | EP2069330A1 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| 06/17/2009 | EP2069318A1 Phenyl derivatives and their use as immunomodulators |
| 06/17/2009 | EP2069314A1 Pyrimidines derivatives and their use as kinase inhibitors |
| 06/17/2009 | EP2069308A2 Azonafide derived tumor and cancer targeting compounds |
| 06/17/2009 | EP2069297A1 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs |
| 06/17/2009 | EP2069296A2 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs |
| 06/17/2009 | EP2069291A1 Hdac inhibitors |
| 06/17/2009 | EP2068938A2 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
| 06/17/2009 | EP2068921A2 High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| 06/17/2009 | EP2068911A2 Methods for treating cancer |
| 06/17/2009 | EP2068894A1 Use of cis-rhenium (iii) diadamantate compounds for potentiating the antitumoral activity of platinium complexes |
| 06/17/2009 | EP2068891A2 Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| 06/17/2009 | EP2068880A1 Method for treating cancer harboring egfr mutations |
| 06/17/2009 | EP2068877A2 Compounds and methods of modulating angiogenesis |
| 06/17/2009 | EP2068876A2 Aqueous formulation comprising an antitumor agent |
| 06/17/2009 | EP2068874A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 06/17/2009 | EP2068871A1 Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
| 06/17/2009 | EP2068870A2 Thiophene compounds |
| 06/17/2009 | EP2068864A2 Therapeutic uses of urolithins |
| 06/17/2009 | EP2068839A2 Pharmaceutical compositions comprising nilotinib or its salt |
| 06/17/2009 | EP1877409B1 Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof |
| 06/17/2009 | EP1866306B1 Imidazopyridine derivatives useful as inos inhibitors |
| 06/17/2009 | EP1740591B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 06/17/2009 | EP1655036A4 Method for treating oncological diseases |
| 06/17/2009 | EP1602669B1 Antibody against a tumor-specific antigen as target |
| 06/17/2009 | EP1565431B1 Cannabinoid receptor ligands |
| 06/17/2009 | EP1542990B1 Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| 06/17/2009 | EP1485381B1 Azolylaminoazine as inhibitors of protein kinases |
| 06/17/2009 | EP1485375B1 Pyrimidine compounds |
| 06/17/2009 | EP1472230B1 Ansamycins having improved pharmacological and biological properties |
| 06/17/2009 | EP1439839B1 A combination comprising combretastatin and anticancer agents |
| 06/17/2009 | EP1409544B1 Human dr4 antibodies and uses thereof |
| 06/17/2009 | EP1390378B1 Pharmaceutically active uridine esters |
| 06/17/2009 | CN100500692C Novel LHRH antagonists, preparation method and pharmaceutical use thereof |
| 06/17/2009 | CN100500663C N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
| 06/17/2009 | CN100500654C Tetrahydrocarbazol derivatives as ligands for g-protein-coupled receptors (gpcr) |
| 06/17/2009 | CN100500193C Extract from decoction of rehmannia including six elements, combination of medication, and medical use |
| 06/17/2009 | CN100500138C Xiaoaiping preparation against cancers and its making method |
| 06/16/2009 | US7547794 antiproliferative agents; antiinflammatory agents; neurodegenerative agents; autoimmune diseases; viricides |
| 06/16/2009 | US7547782 Met kinase inhibitors |
| 06/16/2009 | US7547780 Dihydropteridione intermediate compounds |
| 06/16/2009 | US7547759 Stimulating cytotoxic T-lymphocytes |
| 06/16/2009 | US7547728 (N-(4-nitro-3-trifluoromethyl)phenyl)-(2S)-3-(4- (acetylamino) phenoxy)-2-hydroxy-2-methylpropanamide) derivatives |
| 06/16/2009 | US7547716 Sulfonamide derivatives |
| 06/16/2009 | US7547711 Heterocyclic inhibitors of kinases |
| 06/16/2009 | US7547695 Pyridopyrimidinones |
| 06/16/2009 | US7547451 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease |
| 06/16/2009 | US7547441 PAI-2 conjugates for the treatment and imaging of cancer |
| 06/16/2009 | US7547439 Elicit immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2; polypeptide |
| 06/16/2009 | US7547438 CD40-binding activating antibodies |
| 06/16/2009 | US7547321 Removable stent and method of using the same |
| 06/16/2009 | CA2476934C Stabilized tnfr-fc composition comprising arginine |
| 06/16/2009 | CA2405136C Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
| 06/16/2009 | CA2399910C Mammalian secreted group iii phospholipase a2 |